ANGLE PLC participated in the 14th European Breast Cancer Conference (EBCC) in Milan, Italy, showcasing two posters highlighting the utility of the company's new Portrait+ CTC Staining Kit and Portrait HER2 assay. The conference focused on multidisciplinary, high-quality clinical and translational research, with an emphasis on innovation and technology in the management of breast cancer. ANGLE presented data demonstrating the importance of using its Parsortix system combined with the Portrait+ CTC Staining Kit for the isolation and analysis of a range of CTC phenotypes and CTC clusters, both of which are crucial in cancer progression and metastasis.

The study results emphasized the significance of using ANGLE's Parsortix system combined with the Portrait+ CTC Staining Kit to enable the isolation and analysis of a range of CTC phenotypes and CTC clusters, both of which are important in cancer progression and metastasis. The Parsortix system was observed to harvest CTC clusters in 75% of the CTC-positive patients, which is crucial given the increased metastatic potential of CTC clusters compared to single CTCs. The company's unique cassette design is suited to capturing and harvesting clusters, which is often difficult with other CTC systems.

ANGLE also presented an IF assay for HER2 protein identification on CTCs isolated and harvested using the Parsortix system from the peripheral blood of metastatic breast cancer (MBC) patients. The results from an in-house study in 26 patients found that CTCs overexpressing HER2 were present at similar levels in patients that had HER2+ or HER2- tumors by primary tissue biopsy. The study demonstrated that the HER2 status between primary tumors and CTCs can diverge, and the analysis of HER2 expression on CTCs has the potential to help guide clinical decision making in MBC patients, allowing for regular monitoring and tracking of treatment and/or disease progression.

ANGLE's Chief Scientific Officer, Karen Miller, expressed delight at having two posters presented at the EBCC conference, further demonstrating the potential utility of ANGLE's sample-to-answer Parsortix system and Portrait imaging assays for reliable and repeatable assessment of biomarkers in a range of solid tumors, including breast. The company looks forward to discussions with translational researchers and industry representatives at the conference to explore opportunities for sales, collaboration, and partnerships.